|
|
(more...)
, (less...)
Add to My Group(s)
Add to My Group(s)
By Robert Fiddaman Dip.Couns MOC & MSFTR (about the author)
Become a Fan -- Page 2 of 4 page(s)
The Solvay press office[2] ran with such spin as:
"Being an SSRI, it inhibits the re-uptake of serotonin, a substance in the brain that plays an important role in mental health disorders like depression and OCD"
and
"Experts believe that depression is under-recognized in Japan."
Solvay threw in the clincher with:
"Like in many other countries mental illness is often considered to be profoundly stigmatizing, not just to patients but also to their families. Depression and obsessive-compulsive disorders are complicated diagnoses to make with many patients going unrecognized."
A great way to target a nation who had kept everything being the privacy of their own closed doors for decades. An illness that up until the launch of drugs that was never even recognized in Japan.
A year later, pharmaceutical big boys, GlaxoSmithKline, launched Paxil into the lives of this once peaceful nation.
Koji Nakagawa, GlaxoSmithKline's product manager for Paxil, explained:
"When other pharmaceutical companies were giving up on developing antidepressants in Japan, we went ahead for a very simple reason: the successful marketing in the United States and Europe."[3]
As Nakagawa put it: "People didn't know they were suffering from a disease. We felt it was important to reach out to them."
So, GlaxoSmithKline reached out with:
"Depression is a disease that anyone can get. It can be cured by medicine. Early detection is important."
Paxil-pushing Glaxo reps visit selected doctors an average of twice a week. Awareness campaigns taught doctor's and the public to recognize the following symptoms of depression (the translation is the GSK's):
"Head feels heavy, cannot sleep, stiff shoulders, backache, tired and lazy, no appetite, not intrigued, feel depressed."
Psychiatrist Yutaka Ono applauds raising awareness about depression, but GlaxoSmithKline's marketing made him uncomfortable:
Become a Fan -- Page 2 of 4 page(s)
"Being an SSRI, it inhibits the re-uptake of serotonin, a substance in the brain that plays an important role in mental health disorders like depression and OCD"
and
"Experts believe that depression is under-recognized in Japan."
Solvay threw in the clincher with:
"Like in many other countries mental illness is often considered to be profoundly stigmatizing, not just to patients but also to their families. Depression and obsessive-compulsive disorders are complicated diagnoses to make with many patients going unrecognized."
A great way to target a nation who had kept everything being the privacy of their own closed doors for decades. An illness that up until the launch of drugs that was never even recognized in Japan.
A year later, pharmaceutical big boys, GlaxoSmithKline, launched Paxil into the lives of this once peaceful nation.
Koji Nakagawa, GlaxoSmithKline's product manager for Paxil, explained:
"When other pharmaceutical companies were giving up on developing antidepressants in Japan, we went ahead for a very simple reason: the successful marketing in the United States and Europe."[3]
As Nakagawa put it: "People didn't know they were suffering from a disease. We felt it was important to reach out to them."
So, GlaxoSmithKline reached out with:
"Depression is a disease that anyone can get. It can be cured by medicine. Early detection is important."
Paxil-pushing Glaxo reps visit selected doctors an average of twice a week. Awareness campaigns taught doctor's and the public to recognize the following symptoms of depression (the translation is the GSK's):
"Head feels heavy, cannot sleep, stiff shoulders, backache, tired and lazy, no appetite, not intrigued, feel depressed."
Psychiatrist Yutaka Ono applauds raising awareness about depression, but GlaxoSmithKline's marketing made him uncomfortable:
The Medicines and Healthcare products Regulatory Agency (MHRA) - The FDA's equivalent in the UK - need a thorough impartial investigation. Their own Chief Executive refuses to budge on his stance that Seroxat (Paxil) is safe.
See (more...)
See (more...)
The views expressed in this article are the sole responsibility of the author
and do not necessarily reflect those of this website or its editors.
 Contact Author |
Contact Editor |
 View Authors' Articles |
Comments
The time limit for entering new comments on this article has expired.
This limit can be removed. Our paid membership program is designed to give you many benefits, such as removing this time limit. To learn more, please click here.
| No comments |